- Home
- GEG vs IMA Comparison
GEG vs IMA Comparison
Compare GEG & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GEG | IMA |
|---|---|---|
| Founded | 1994 | 2019 |
| Country | United States | United States |
| Employees | 50 | 17 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.0M | 66.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GEG | IMA |
|---|---|---|
| Price | $2.15 | $5.38 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | ★ 11.4K | 8.4K |
| Earning Date | 05-11-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.80 | $3.94 |
| 52 Week High | $3.51 | $17.50 |
Technical Indicators
Market Signals| Indicator | GEG | IMA |
|---|---|---|
| Relative Strength Index (RSI) | 45.79 | 36.80 |
| Support Level | $2.05 | $5.36 |
| Resistance Level | $2.19 | $6.08 |
| Average True Range (ATR) | 0.06 | 0.30 |
| MACD | -0.01 | -0.06 |
| Stochastic Oscillator | 0.00 | 6.12 |
Price Performance
Historical ComparisonAbout GEG Great Elm Group Inc.
Great Elm Group Inc operates as an alternative asset manager focused on growing a scalable and diversified portfolio of long-duration and permanent capital vehicles across credit, real estate, specialty finance, and other alternative strategies. Along with its subsidiaries, it manages Great Elm Capital Corp, a publicly traded business development company, and Monomoy Properties REIT, LLC, an industrial-focused real estate investment trust, in addition to other investments.
About IMA ImageneBio Inc.
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.